Particella Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 17

Particella General Information

Description

Developer of an oral lipid nanoparticle technology designed to deliver nucleic acids to the intestinal epithelium. The company focuses on oral mRNA medicines with repeatable dosing and non-immunogenic properties, enabling healthcare providers to administer nucleic acid therapeutics through oral delivery.

Contact Information

Formerly Known As
DNAlite Therapeutics, DNALite
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 665 3rd Street
  • Suite 250
  • San Francisco, CA 94107
  • United States
+1 (713)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 665 3rd Street
  • Suite 250
  • San Francisco, CA 94107
  • United States
+1 (713)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Particella Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 16-Jan-2025 Completed Generating Revenue
10. Secondary Transaction - Private Completed Pre-Clinical Trials
9. Later Stage VC 07-Mar-2023 Completed Pre-Clinical Trials
8. Later Stage VC (Series A) 01-Apr-2022 Completed Pre-Clinical Trials
7. Seed Round 08-Aug-2018 Completed Pre-Clinical Trials
6. Seed Round 22-Dec-2017 Completed Pre-Clinical Trials
5. Accelerator/Incubator 07-Sep-2017 Completed Pre-Clinical Trials
4. Accelerator/Incubator 05-Apr-2017 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Feb-2017 $5K Completed Pre-Clinical Trials
2. Accelerator/Incubator $5K Completed Pre-Clinical Trials
To view Particella’s complete valuation and funding history, request access »

Particella Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A-1
Seed-1c
Seed-1b 518,941 $0.000100 $0.04 $0.48 $0.48 1x $0.48 3.3%
Seed-1a 1,717,621 $0.000100 $0.07 $0.87 $0.87 1x $0.87 10.93%
To view Particella’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Particella Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an oral lipid nanoparticle technology designed to deliver nucleic acids to the intestinal epithelium. The c
Drug Discovery
San Francisco, CA
7 As of 2026

Abingdon, United Kingdom
 

Niel, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Particella Competitors (33)

One of Particella’s 33 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
etherna Formerly VC-backed Niel, Belgium
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
BioNTech Formerly VC-backed Mainz, Germany
You’re viewing 5 of 33 competitors. Get the full list »

Particella Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Particella Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Transitions First Venture Capital Minority
Berkeley SkyDeck Accelerator/Incubator Minority
Berkeley SkyDeck Fund Venture Capital Minority
Angel (individual) Minority
KdT Ventures Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Particella FAQs

  • When was Particella founded?

    Particella was founded in 2016.

  • Where is Particella headquartered?

    Particella is headquartered in San Francisco, CA.

  • What is the size of Particella?

    Particella has 7 total employees.

  • What industry is Particella in?

    Particella’s primary industry is Drug Discovery.

  • Is Particella a private or public company?

    Particella is a Private company.

  • What is Particella’s current revenue?

    The current revenue for Particella is .

  • How much funding has Particella raised over time?

    Particella has raised $13M.

  • Who are Particella’s investors?

    Transitions First, Berkeley SkyDeck, Berkeley SkyDeck Fund, , and KdT Ventures are 5 of 17 investors who have invested in Particella.

  • Who are Particella’s competitors?

    Adaptimmune Therapeutics, etherna, Carisma Therapeutics, Phathom Pharmaceuticals, and BioNTech are some of the 33 competitors of Particella.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process